Evidence review finds that diets low in omega-3 fats and high in omega-6 fats promote Alzheimers disease; antioxidant-rich diets may also reduce risk/severity
by Craig Weatherby
www.vitalchoices.com
(Reprinted with permission)
Alzheimer's disease (AD) is the most common form of dementia, and afflicts some 25 million people worldwide, with half being under 85 years of age.
The causes of AD are not understood and there are no cures or effective treatments.
Genetics play a major role
but a growing body of research suggests that most people can reduce their risk of AD by eating more vegetables, fruits, and fish and fewer processed and prepared foods.
Now, the authors of an evidence review from the University of Turin, Italy conclude that the omega imbalance typical of American and western diets much more omega-6 fat and less omega-3 fat than human bodies need is an under-recognized risk factor (Corsinovi L et al. 2011).
(To learn more about this issue, and the food sources of both kinds of omega fat, see Americas Sickening Omega Imbalance.)
Key Points
Italtian evidence reviewers link the typical American diet's "omega imbalance" to higher Alzheimer's risk.
Findings dovetail with the clear link between heart risk and diets too high in omega-6 fats.
Turin-based team also link food-borne antioxidants to reduced dementia risk/severity.
The Italian researchers review notes recent findings on how dietary lipids (fats and cholesterol) affect the risk of Alzheimer's disease in animals and humans, with a focus on the harm done by oxidation of lipids.
As they wrote, Considerable experimental data suggest the importance, in the pathogenesis of AD, of persistent oxidative stress associated with the presence of oxidation end-products. (Corsinovi L et al. 2011)
The omega-ratio link to cardiovascular and Alzheimers disease
Alzheimers disease shares a number of risk factors with cardiovascular disease (CVD).
These include hypertension (high blood pressure), high non-HDL cholesterol levels, obesity, smoking, atrial fibrillation, angina, and a gene variation called ApoE4.
Having multiple cardiovascular risk factors raises a persons risk of Alzheimers disease more than any single risk factor does, and also speeds the progression of AD (Rosendorff C et al. 2007; Purnell C et al. 2009; de Toledo Ferraz Alves TC et al. 2010).
Another major factor is having the ApoE4 gene, which greatly raises the risk of developing Alzheimers disease and cardiovascular disease alike (Corder EH et al. 1993; Kalmijn S et al. 1996; Barberger-Gateau P et al. 2011).
Some epidemiological studies suggest that omega-3 fatty acids from fish may protect against Alzheimer's disease, while others do not. And most clinical trials testing supplemental omega-3 fish oils have yielded disappointing results.
One reason for such divergent results is that some people carry a variation of the ApoE gene, which plays a key role in the transport of cholesterol and other lipids involved in brain composition and function.
The the effects of omega-3 DHA from fish fat appears minimal in people with the ApoE4 variation (allele) of this gene. Carriers of the ApoE4 gene tend are the most responsive to changes in dietary fat and cholesterol.
Surprisingly, some epidemiological studies suggest omega-3-rich diets reduce cognitive decline only in people who do not carry the ApoE4 gene.
This may be because, as other studies suggest, theres a link between the ApoE4 gene and suffering from dysfunctional metabolism/absorption of dietary omega-3s.
The omega ratio in Alzheimers disease
Were not surprised that the authors believe the balance between omega-3 and omega-6 fatty acids and cholesterol surely plays a crucial role in AD's onset. (Corsinovi L et al. 2011)
A similar link has been shown to exist between peoples dietary omega-3/omega-6 fat ratio and their risk of heart disease
see Heart Group's Omega-6 Advice Takes a Huge Hit in the Omega-3 / Omega-6 Balance section of our news archive.
Growing evidence links excess dietary cholesterol and omega-6 fatty acids and accumulation of their oxidized forms contributes to the onset and progression of Alzheimers disease.
And, based on the conclusions of the new evidence review, the two diseases share another risk factor: a low omega-3/omega-6 fat ratio in a persons diet, which produces a low omega-3/omega-6 ratio in their cell membranes.
A low omega-3/omega-6 ratio creates a pro-inflammatory environment, which in turn promotes oxidation of lipids
a key risk factor for CVD and an increasingly apparent one for Alzheimers disease, too.
As the author of a recent evidence review from Texas Tech University wrote,
chronic inflammation is closely associated with cardiovascular disease, as well as a broad spectrum of neurodegenerative diseases of aging including AD. (Grammas P 2011)
The omega balance is just one of many other factors, including genetics, educational level, exercise, and more.
However, the Italian team emphasized, it may be said that a dietary regimen low in omega-6 PUFA [polyunsaturated fatty acids] and cholesterol, together with the use of antioxidants, including polyphenols, is valuable within a general strategy of prevention of neurodegenerative diseases. (Corsinovi L et al. 2011)
They noted that a balanced intake of omega-3 and omega-6 PUFA is essential for brain homeostasis, while a significantly reduced omega-3/omega-6 PUFA ratio appears to contribute to the onset of AD. (Corsinovi L et al. 2011)
And based on evidence linking a low omega-3/omega-6 ratio, the University of Turin researchers offered advice that physicians, public health officials, and regular people should heed:
A dietary regimen including the intake of a recommended amount of omega-3 PUFA or, better, an appropriate omega-6/omega-3 PUFA ratio, could certainly help to prevent cognitive impairment and, in patients with early AD, would help to delay progression of the disease.
Review also recommends food-borne antioxidants
The Italian team of reviewers also found that the evidence supports the idea that certain of the polyphenol antioxidants abundant in certain plant foods might help prevent AD and other neurodegenerative diseases and assist in treatment of early stages.
We put antioxidant in quote marks because while polyphenols display potent antioxidant powers in the test tube, the amounts that make it into the bloodstream are generally far too low to make much direct impact.
Instead, animal and clinical research shows that even very small amounts of polyphenols in the blood can influence the expression of genes controlling the bodys own antioxidant and anti-inflammatory network (i.e., nutrigenomic effects).
In particular, the researchers noted that several epidemiological studies link lower AD risk to higher intake of polyphenols.
The polyphenols most strongly linked to brain health are flavanols (catechins and procyanidins) which abound in non-Dutched (i.e., not treated with alkali) cocoa, dark chocolate, grapes, berries, and tea (especially green or white tea) and the flavonol called quercetin, which is concentrated in onions and other vegetables.
The take away message is an appealing one: to help keep your brain sharp as you age, drink tea, nibble on extra-dark chocolate, and eat plenty of fatty fish, vegetables, and fruits.
Sources
Barberger-Gateau P, Samieri C, Féart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res. 2011 Aug;8(5):479-91.
Bégin ME, Plourde M, Pifferi F, Cunnane SC. What Is the Link between Docosahexaenoic Acid, Cognitive Impairment, and Alzheimers Disease in the Elderly? In: Montmayeur JP, le Coutre J, editors. SourceFat Detection: Taste, Texture, and Post Ingestive Effects. Boca Raton (FL): CRC Press; 2010. Chapter 19. Frontiers in Neuroscience.
Bergmann C, Sano M. (2006). Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol Res. 28(6):595-604.
Kalmijn S Corder EH et al. (1993). "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families". Science 261 (5123): 921-3.
Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer's disease. Mol Nutr Food Res. 2011 Sep;55 Suppl 2
161-SS172. doi: 10.1002/mnfr.201100208. Epub 2011 Aug 31.
de Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF. Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis. 2010;20(3):749-63. Review.
Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009 Sep 1;73(9):674-80.
Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr. 2009 Jul;90(1):170-6. Epub 2009 May 27.
Forette F et al. (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 352(9137):1347-51.
Frishman WH. (2002). Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis. 4(6):380-6.
Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation. 2011 Mar 25;8:26. Review.
Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. (1996). Cerebrovascular disease, the apolipoprotein ε 4 allele, and cognitive decline in a community-based study of elderly men. Stroke. 27: 2230-5.
Kivipelto et al. (2001). Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 322(7300):1447-51.
Kivipelto et al. (2005). Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 62(10):1556-60.
Kröger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, Ayotte P, Laurin D. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr. 2009 Jul;90(1):184-92. Epub 2009 May 27.
Launer LJ et al. (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 21(1):49-55.
Mielke MM et al. (2007). Vascular factors predict rate of progression in Alzheimer disease. Neurol. 69:1850-8.
Miida T, Takahashi A, Ikeuchi T. (2007). Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther. 113(2):378-93.
Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, Spalletta G, di Iulio F, Pettenati C, Cravello L, Caltagirone C. Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors. J Neurol. 2009 Aug;256(8):1288-95. Epub 2009 Apr 8.
Newman et al. (2005 ). Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 53(7):1101-7.
Notkola et al. (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 17(1):14-20.
Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):1-10. Review.
Qiu C, Winblad B, Fratiglioni L. (2005). The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4(8):487-99.
Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol. 2007 May-Jun;16(3):143-9. Review.
Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B; REAL.FR Study Group. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology. 2009 Oct 27;73(17):1359-66.
SourceFat Detection: Taste, Texture, and Post Ingestive Effects. Boca Raton (FL): CRC Press; 2010. Chapter 19. In: Montmayeur JP, le Coutre J, editors.
Spiteller G. The relation of lipid peroxidation processes with atherogenesis: a new theory on atherogenesis. Mol Nutr Food Res. 2005 Nov;49(11):999-1013. Review.
Van Broeck B, Van Broeckhoven C, Kumar-Singh S. (2007). Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis.;4(5):349-65.
Wolozin B, Bednar MM. (2006). Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res. 2006 Sep;28(6):630-6.